X4 Pharmaceuticals (XFOR) Share-based Compensation (2017 - 2025)

X4 Pharmaceuticals has reported Share-based Compensation for 9 years, with the latest figure at $2.3 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation rose 2.44% year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2025 stood at $4.3 million (down 47.61% YoY), and the FY2025 full-year result was $4.3 million, down 47.61% from the prior year.
• Share-based Compensation for Q4 2025 stood at $2.3 million, up from $760000.0 in the prior quarter.
• The five-year high for Share-based Compensation was $2.5 million in Q4 2023, with the low at $519000.0 in Q1 2025.
• Historically, Share-based Compensation has averaged $1.6 million across 5 years, with a median of $1.6 million in 2021.
• Annual changes were most pronounced in 2023 — Share-based Compensation jumped 129.36% — and 2025, when it plunged 70.16%.
• X4 Pharmaceuticals' Share-based Compensation stood at $1.6 million in 2021, then sank by 31.2% to $1.1 million in 2022, then jumped by 129.36% to $2.5 million in 2023, then dropped by 12.68% to $2.2 million in 2024, then increased by 2.44% to $2.3 million in 2025.
• The last three Share-based Compensation figures came in at $2.3 million (Q4 2025), $760000.0 (Q3 2025), and $748000.0 (Q2 2025), per Business Quant data.